Tags

Type your tag names separated by a space and hit enter

Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double-blind placebo-controlled trial.
Allergy 2005; 60(4):494-500A

Abstract

BACKGROUND

Probiotic bacteria are suggested to reduce symptoms of the atopic eczema/dermatitis syndrome (AEDS) in food-allergic infants. We aimed to investigate whether probiotic bacteria have any beneficial effect on AEDS.

METHODS

Follow-up of severity of AEDS by the Severity Scoring of Atopic Dermatitis (SCORAD) index in 230 infants with suspected cow's milk allergy (CMA) receiving, in a randomized double-blinded manner, concomitant with elimination diet and skin treatment, Lactobacillus GG (LGG), a mixture of four probiotic strains, or placebo for 4 weeks. Four weeks after the treatment, CMA was diagnosed with a double-blind placebo-controlled (DBPC) milk challenge in 120 infants.

RESULTS

In the whole group, mean SCORAD (at baseline 32.5) decreased by 65%, but with no differences between treatment groups immediately or 4 weeks after the treatment. No treatment differences were observed in infants with CMA either. In IgE-sensitized infants, however, the LGG group showed a greater reduction in SCORAD than did the placebo group, -26.1 vs-19.8 (P=0.036), from baseline to 4 weeks after the treatment. Exclusion of infants who had received antibiotics during the study reinforced the findings in the IgE-sensitized subgroup.

CONCLUSION

Treatment with LGG may alleviate AEDS symptoms in IgE-sensitized infants but not in non-IgE-sensitized infants.

Authors+Show Affiliations

The Skin and Allergy Hospital, University of Helsinki, Helsinki, Finland.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

15727582

Citation

Viljanen, M, et al. "Probiotics in the Treatment of Atopic Eczema/dermatitis Syndrome in Infants: a Double-blind Placebo-controlled Trial." Allergy, vol. 60, no. 4, 2005, pp. 494-500.
Viljanen M, Savilahti E, Haahtela T, et al. Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double-blind placebo-controlled trial. Allergy. 2005;60(4):494-500.
Viljanen, M., Savilahti, E., Haahtela, T., Juntunen-Backman, K., Korpela, R., Poussa, T., ... Kuitunen, M. (2005). Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double-blind placebo-controlled trial. Allergy, 60(4), pp. 494-500.
Viljanen M, et al. Probiotics in the Treatment of Atopic Eczema/dermatitis Syndrome in Infants: a Double-blind Placebo-controlled Trial. Allergy. 2005;60(4):494-500. PubMed PMID: 15727582.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double-blind placebo-controlled trial. AU - Viljanen,M, AU - Savilahti,E, AU - Haahtela,T, AU - Juntunen-Backman,K, AU - Korpela,R, AU - Poussa,T, AU - Tuure,T, AU - Kuitunen,M, PY - 2005/2/25/pubmed PY - 2005/6/21/medline PY - 2005/2/25/entrez SP - 494 EP - 500 JF - Allergy JO - Allergy VL - 60 IS - 4 N2 - BACKGROUND: Probiotic bacteria are suggested to reduce symptoms of the atopic eczema/dermatitis syndrome (AEDS) in food-allergic infants. We aimed to investigate whether probiotic bacteria have any beneficial effect on AEDS. METHODS: Follow-up of severity of AEDS by the Severity Scoring of Atopic Dermatitis (SCORAD) index in 230 infants with suspected cow's milk allergy (CMA) receiving, in a randomized double-blinded manner, concomitant with elimination diet and skin treatment, Lactobacillus GG (LGG), a mixture of four probiotic strains, or placebo for 4 weeks. Four weeks after the treatment, CMA was diagnosed with a double-blind placebo-controlled (DBPC) milk challenge in 120 infants. RESULTS: In the whole group, mean SCORAD (at baseline 32.5) decreased by 65%, but with no differences between treatment groups immediately or 4 weeks after the treatment. No treatment differences were observed in infants with CMA either. In IgE-sensitized infants, however, the LGG group showed a greater reduction in SCORAD than did the placebo group, -26.1 vs-19.8 (P=0.036), from baseline to 4 weeks after the treatment. Exclusion of infants who had received antibiotics during the study reinforced the findings in the IgE-sensitized subgroup. CONCLUSION: Treatment with LGG may alleviate AEDS symptoms in IgE-sensitized infants but not in non-IgE-sensitized infants. SN - 0105-4538 UR - https://www.unboundmedicine.com/medline/citation/15727582/Probiotics_in_the_treatment_of_atopic_eczema/dermatitis_syndrome_in_infants:_a_double_blind_placebo_controlled_trial_ L2 - https://doi.org/10.1111/j.1398-9995.2004.00514.x DB - PRIME DP - Unbound Medicine ER -